AbbVie Inc. Shares Outstanding 2010-2024 | ABBV
AbbVie Inc. shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- AbbVie Inc. shares outstanding for the quarter ending December 31, 2024 were 1.773B, a 0% increase year-over-year.
- AbbVie Inc. 2024 shares outstanding were 1.773B, a 0% decline from 2023.
- AbbVie Inc. 2023 shares outstanding were 1.773B, a 0.28% decline from 2022.
- AbbVie Inc. 2022 shares outstanding were 1.778B, a 0.06% increase from 2021.
AbbVie Inc. Annual Shares Outstanding
(Millions of Shares) |
| 2024 |
1,773 |
| 2023 |
1,773 |
| 2022 |
1,778 |
| 2021 |
1,777 |
| 2020 |
1,673 |
| 2019 |
1,484 |
| 2018 |
1,546 |
| 2017 |
1,603 |
| 2016 |
1,631 |
| 2015 |
1,637 |
| 2014 |
1,610 |
| 2013 |
1,604 |
| 2012 |
1,577 |
| 2011 |
1,577 |
| 2010 |
1,577 |
| 2009 |
|
AbbVie Inc. Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-12-31 |
1,773 |
| 2024-09-30 |
1,772 |
| 2024-06-30 |
1,771 |
| 2024-03-31 |
1,773 |
| 2023-12-31 |
1,773 |
| 2023-09-30 |
1,771 |
| 2023-06-30 |
1,771 |
| 2023-03-31 |
1,776 |
| 2022-12-31 |
1,778 |
| 2022-09-30 |
1,776 |
| 2022-06-30 |
1,776 |
| 2022-03-31 |
1,778 |
| 2021-12-31 |
1,777 |
| 2021-09-30 |
1,777 |
| 2021-06-30 |
1,776 |
| 2021-03-31 |
1,775 |
| 2020-12-31 |
1,673 |
| 2020-09-30 |
1,774 |
| 2020-06-30 |
1,647 |
| 2020-03-31 |
1,484 |
| 2019-12-31 |
1,484 |
| 2019-09-30 |
1,483 |
| 2019-06-30 |
1,484 |
| 2019-03-31 |
1,483 |
| 2018-12-31 |
1,546 |
| 2018-09-30 |
1,515 |
| 2018-06-30 |
1,572 |
| 2018-03-31 |
1,596 |
| 2017-12-31 |
1,603 |
| 2017-09-30 |
1,603 |
| 2017-06-30 |
1,600 |
| 2017-03-31 |
1,603 |
| 2016-12-31 |
1,631 |
| 2016-09-30 |
1,640 |
| 2016-06-30 |
1,632 |
| 2016-03-31 |
1,625 |
| 2015-12-31 |
1,637 |
| 2015-09-30 |
1,664 |
| 2015-06-30 |
1,633 |
| 2015-03-31 |
1,608 |
| 2014-12-31 |
1,610 |
| 2014-09-30 |
1,610 |
| 2014-06-30 |
1,608 |
| 2014-03-31 |
1,609 |
| 2013-12-31 |
1,604 |
| 2013-09-30 |
1,605 |
| 2013-06-30 |
1,609 |
| 2013-03-31 |
1,605 |
| 2012-12-31 |
1,577 |
| 2012-09-30 |
1,577 |
| 2012-06-30 |
1,577 |
| 2012-03-31 |
1,577 |
| 2011-12-31 |
1,585 |
| 2011-09-30 |
1,300 |
| 2011-06-30 |
1,571 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$356.743B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
